Clinical Trial Update: Dose-Escalation Study on Safety and Immunogenicity of VPM1002 in Comparison to BCG in Healthy Volunteers in South Africa [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study assessing safety and immunogenicity of VPM1002 compared with BCG in healthy volunteers in South Africa has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• BCG (Bacillus Calmette-Guérin)
• VPM1002 (recombinant Bacillus Calmette-Guérin vaccine (rBCG))

Snippet

Sponsor: Serum Life Science Europe GmbH | Conditions: Tuberculosis | Phase 1 | Status: COMPLETED